Teodor E Yordanov1, Victoria E B Hipolito2, Gudrun Liebscher1, Georg F Vogel1,3, Taras Stasyk1, Caroline Herrmann1, Stephan Geley4, David Teis1, Roberto J Botelho2, Michael W Hess5, Lukas A Huber1,6. 1. Division of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. 2. Department of Chemistry and Biology and the Graduate Program in Molecular Science, Ryerson University, Toronto, Ontario, Canada. 3. Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria. 4. Division of Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. 5. Division of Histology and Embryology, Medical University of Innsbruck, Innsbruck, Austria. 6. Austrian Drug Screening Institute, ADSI, Innsbruck, Austria.
Abstract
Mechanisms that control lysosomal function are essential for cellular homeostasis. Lysosomes adapt in size and number to cellular needs but little is known about the underlying molecular mechanism. We demonstrate that the late endosomal/lysosomal multimeric BLOC-1-related complex (BORC) regulates the size of these organelles via PIKfyve-dependent phosphatidylinositol-3,5-bisphosphate [PI(3,5)P2 ] production. Deletion of the core BORC component Diaskedin led to increased levels of PI(3,5)P2 , suggesting activation of PIKfyve, and resulted in enhanced lysosomal reformation and subsequent reduction in lysosomal size. This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex. Consistently, in response to glucose limitation, AMPK activated PIKfyve, which induced lysosomal reformation with increased baseline autophagy and was coupled to a decrease in lysosomal size. These adaptations of the late endosomal/lysosomal system reversed under glucose replete growth conditions. In summary, our results demonstrate that BORC regulates lysosomal reformation and size in response to glucose availability.
Mechanisms that control lysosomal function are essential for cellular homeostasis. Lysosomes adapt in size and number to cellular needs but little is known about the underlying molecular mechanism. We demonstrate that the late endosomal/lysosomal multimeric BLOC-1-related complex (BORC) regulates the size of these organelles via PIKfyve-dependent phosphatidylinositol-3,5-bisphosphate [PI(3,5)P2 ] production. Deletion of the core BORC component Diaskedin led to increased levels of PI(3,5)P2 , suggesting activation of PIKfyve, and resulted in enhanced lysosomal reformation and subsequent reduction in lysosomal size. This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex. Consistently, in response to glucose limitation, AMPK activated PIKfyve, which induced lysosomal reformation with increased baseline autophagy and was coupled to a decrease in lysosomal size. These adaptations of the late endosomal/lysosomal system reversed under glucose replete growth conditions. In summary, our results demonstrate that BORC regulates lysosomal reformation and size in response to glucose availability.
AMP‐activated protein kinasebiogenesis of lysosome‐related organelles complex‐1BLOC‐1‐related complexchloroquineearly endosomal antigen 1immunofluorescenceknock outlysosome‐associated membrane protein 1late endosomal/lysosomal adaptor, MAPK and mTOR activatormitogen‐activated protein kinasesmechanistic target of rapamycinmolecular weightpost‐nuclear supernatantphosphoinositides; Phosphatidylinositol 3,5 bisphosphatesteady statetotal membranesWestern blotting
INTRODUCTION
The endocytic system of cells comprises a network of compartments, which are dynamically interacting with each other and with numerous other cellular organelles, such as the Golgi apparatus, the endoplasmic reticulum and the plasma membrane.1 The most mature organelle of the endosomal system is the lysosome, it participates in numerous vital cellular processes, such as microbial killing and antigen presentation, detoxification, recycling of metabolic building blocks (amino acids, glucose and cholesterol), apoptosis, cell migration, cancer invasion and metastasis.2, 3 To adapt to cellular needs and environmental conditions, lysosomes must reform and continuously adapt in size and number. Many lysosomal functions depend on the position of the organelle in the cell. Lysosomes move readily back and forth between the perinuclear region and the cell periphery,4 with a majority of them showing a steady state distribution close to the Microtubule Organizing Center (MTOC). The bidirectional movement of lysosomes along microtubules is important for distributing the degradative activity of lysosomes to all regions of the cell, as well as for many other lysosomal functions including antigen presentation, microbial killing, autophagy, metabolic signaling, cell adhesion and migration and tumor invasion and metastasis.2, 3, 5, 6, 7To control lysosomal function and signaling capacity, many scaffolding complexes populate the limiting membrane of lysosomes, where they recruit and orchestrate multiple signal transduction cascades.Two such multimeric endosomal scaffold complexes are the biogenesis of lysosome‐related organelles complex 1 (BLOC‐1) and the late endosomal/lysosomal BLOC‐1‐related complex (BORC). BLOC‐1 comprises the subunits BLOS1, BLOS2, BLOS3, Snapin, Pallidin, Muted, Cappuccino and Dysbindin.8, 9, 10, 11 Recent observations suggest that BLOC‐1 may participate in the biogenesis of recycling endosomes by coordinating endosomal tubule generation.12BORC consists only of a subset of BLOC proteins, BLOS1, BLOS2 and Snapin, and additionally employs the specific subunits of this complex KXD1, MEF2BNB, Myrlysin, Lyspersin and Diaskedin.2 BORC associates with the cytoplasmic leaflet of the limiting late endosomal/lysosomal membrane, at least partially through an N‐terminal myristoyl group on Myrlysin.2 The main function attributed to BORC is the recruitment of the small Arf‐like GTPase Arl8b from the cytoplasm onto the lysosomal membrane, which promotes the kinesin‐dependent movement of lysosomes toward the cell periphery along microtubule tracks.2, 13 Consistently, BORC deficient cells accumulate lysosomes in the perinuclear region and exhibit reduced spreading and motility. Recently, we demonstrated that the C‐terminus of the BORC subunit Lyspersin is essential and sufficient for BORC‐dependent recruitment of Arl8b to lysosomes.14 In addition, we established Lyspersin as the linker between BORC and LAMTOR/Ragulator complexes and identified LAMTOR/Ragulator as a negative regulator of BORC‐ and Arl8b‐dependent lysosomal transport to the cell periphery. Importantly, growth factor stimulation as well as amino acid availability control lysosomal positioning through a LAMTOR/Ragulator dependent, but mammalian target of rapamycin complex 1 (mTORC1)‐independent pathway.14, 15 The BORC complex together with Arl8b is required to allow the movement of a subset of lysosomes to the periphery of the cell.2, 16Here, we present evidence that BORC is also involved in the control of late endosomal/lysosomal size, which is mediated via regulation of phosphatidylinositol‐3,5‐bisphosphate [PI(3,5)P2] levels. Cells lacking the core BORC components, Diaskedin or Myrlysin had smaller late endosomes/lysosomes compared to their wild type (WT) counterparts. In contrast, deletion of a third core BORC component Lyspersin did not affect the size of these organelles, pointing toward a specific function of Diaskedin and Myrlysin in this process. This size difference was retained even under conditions, where fundamental lysosomal properties such as pH were compromised. The morphological changes of the late endosomes/lysosomes in BORC deficient cells were caused by enhanced lysosomal reformation—a process, directly linked to PIKfyve function. Recently, it was reported that inhibiting PIKfyve impairs generation of terminal lysosomes, since PIKfyve activity regulates extensive membrane remodeling that initiates reformation of lysosomes from acidic and hydrolase‐active, enlarged endolysosomes.17, 18Upstream from PIKfyve, we have identified AMPK as key activator. Endosomal size regulation was correlated with cellular energy status and AMPK activation. Under glucose starvation, a well‐established activator of AMPK signaling,19, 20 a significant reduction of late endosomal size in WT cells was achieved, which was morphologically undistinguishable from the Diaskedin deletion mutant, bearing intrinsically activated AMPK signaling. Organelle size could then be reverted to the steady state dimensions upon glucose restimulation, pointing toward an energy sensing involvement of the BORC complex. In addition, the LAMTOR/Ragulator complex was found as a modulator of this process. LAMTOR/Ragulator deficient cells phenocopy BORC deletion mutants in terms of endosomal/lysosomal size and abundance. Overall, our data suggest that BORC controls the size of late endosomes and lysosomes in addition to its established role in controlling lysosomal transport. Finally, baseline autophagy in Diaskedin and Myrlysin deletion mutants was also significantly upregulated. We could link this phenotype to the decrease of endosomal/lysosomal size, as both processes are ultimately regulated by PI(3,5)P2 production.
RESULTS
Deletion of the BORC component Diaskedin reduces the size of lysosomes
Recently, we and others14, 15 have demonstrated that the BORC subunit Lyspersin is specifically required for establishing the interaction between BORC and LAMTOR/Ragulator on the surface of late endosomes/lysosomes. Therefore, we hypothesized that other BORC subunits might as well fulfill dedicated functions. To test this assumption, we first selected Diaskedin for further analysis since it was shown to interact in equimolar ratios with Myrlysin, the proposed membrane anchor of the complex.21 Upon CRISPR/Cas9 mediated knock‐out (KO) of Diaskedin in HeLa cells, we noticed that the protein levels of the BORC subunit, Lyspersin, were downregulated, whereas the protein levels of the late endosomal marker lysosome‐associated membrane protein 1 (LAMP1) were upregulated (Figure 1A). Consistently, the morphology of the late endosomal/lysosomal system was severely affected in Diaskedin deficient (KO) cells. The total number of LAMP1 positive late endosomes/lysosomes was significantly increased compared with WT cells (Figure 1B,C) and those organelles typically clustered in the perinuclear region (Figure 1B,F), which resembled the phenotype of Lyspersin depleted cells.14 The number of early endosomal antigen 1 (EEA1) positive early endosomes was comparable in Diaskedin KO and WT cells (Figure 1B,C). Super resolution stimulated emission depletion (STED) microscopy revealed that the diameter of individual LAMP1 positive late endosomes/lysosomes was significantly reduced in Diaskedin KO cells, compared with WT HeLa cells (Figure 1D,E). Additionally, morphometry from electron microscopy (EM) images (Figure 1F) of high‐pressure frozen HeLa cells further confirmed an increased frequency of lysosomes, their perinuclear accumulation, as well as their smaller diameter upon Diaskedin deletion (Figure 1F,G).
Figure 1
Deletion of Diaskedin causes reduction of late endosomal size in HeLa. (A) WB of cell lysates of HeLa WT and Diaskedin KO cells. (B) Single plane images of Z‐stacks of WT HeLa and Diaskedin KO, stained with the late endosomal marker LAMP1 and the early endosomal marker EEA1. Scale bars: 10 μm. (C) Frequency of endosomes in WT and Diaskedin KO HeLa based on analyses of Z‐stack confocal images. Total endosomal count was acquired using automated counting algorithm in Imaris from 10 cells per genotype. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO samples for each endosomal population (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Super resolution STED images of WT HeLa and Diaskedin KO. Inserts show magnification of the selected areas. Scale bars: 10um. (E) Endosomal diameters in WT and Diaskedin KO HeLa based on measurements from superresolution STED images. Manual size measurement of at least 100 endosomes from at least six cells per genotype was made. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO samples (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (F) Electron microscopy (EM) of cryofixed HeLa WT and Diaskedin KO cells with perinuclear clustering of lysosomes (arrows) in Diaskedin KO cells (m: mitochondria, n: nucleus). Scale bars: 2 μm. Inserts show high magnification views of lysosomes, one of which with a putative constriction site (double arrow‐head) in KO cells. Scale bars: 200 nm. (G) Frequency of lysosomes per 100 square‐micron cytoplasm and lysosomal size in WT and Diaskedin KO HeLa cells as measured on EM images (>550 lysosomes from >25 cells per genotype). Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Deletion of Diaskedin causes reduction of late endosomal size in HeLa. (A) WB of cell lysates of HeLa WT and Diaskedin KO cells. (B) Single plane images of Z‐stacks of WT HeLa and Diaskedin KO, stained with the late endosomal marker LAMP1 and the early endosomal marker EEA1. Scale bars: 10 μm. (C) Frequency of endosomes in WT and Diaskedin KO HeLa based on analyses of Z‐stack confocal images. Total endosomal count was acquired using automated counting algorithm in Imaris from 10 cells per genotype. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO samples for each endosomal population (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Super resolution STED images of WT HeLa and Diaskedin KO. Inserts show magnification of the selected areas. Scale bars: 10um. (E) Endosomal diameters in WT and Diaskedin KO HeLa based on measurements from superresolution STED images. Manual size measurement of at least 100 endosomes from at least six cells per genotype was made. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO samples (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (F) Electron microscopy (EM) of cryofixed HeLa WT and Diaskedin KO cells with perinuclear clustering of lysosomes (arrows) in Diaskedin KO cells (m: mitochondria, n: nucleus). Scale bars: 2 μm. Inserts show high magnification views of lysosomes, one of which with a putative constriction site (double arrow‐head) in KO cells. Scale bars: 200 nm. (G) Frequency of lysosomes per 100 square‐micron cytoplasm and lysosomal size in WT and Diaskedin KO HeLa cells as measured on EM images (>550 lysosomes from >25 cells per genotype). Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between WT and KO (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Reduction of endosomal size upon deletion of different BORC components in HT1080 cells
To corroborate these observations in another cell line, we generated a Diaskedin KO in the fibrosarcoma cells HT1080, together with the respective rescue cell line by re‐expressing HA‐tagged WT Diaskedin (Figure 2A). The loss of Diaskedin in these cells was also accompanied by LAMP1 upregulation and a slight downregulation of Lyspersin (Figure 2A). Interestingly, roughly 25% of WT HT1080 cells harbor already under standard growth conditions a population of considerably enlarged late endocytic compartments (often >2 μm in diameter; Figure 2B‐D). These oversized endocytic compartments were positive for several marker proteins of late endosomes/lysosomes (LAMP1, CD63 and Cathepsin D), but were devoid of EEA1 and M6PR (Supplementary Figure S1A‐C). The functional properties of the oversized compartments, such as luminal pH, accumulation of fluid phase markers and degradative capacity also appeared comparable to the other, normal‐sized late endosomes/lysosomes in the same cells (Figure 2B and Movie S1). Thus, we concluded that those oversized endocytic compartments were catabolically active late endosomes/lysosomes and we refer to them as “enlarged late endosomes” hereafter. Their exaggerated diameter greatly facilitated light microscopic monitoring of organelle alterations. Importantly, upon Diaskedin deletion, there was a lower frequency of cells with enlarged endosomes (Figure 2C). In the Diaskedin HT1080 rescue cell line, re‐expressing HA‐tagged WT Diaskedin, the frequency of enlarged late endosomes was similar to WT HT1080 cells (Figure 2A,C).
Figure 2
Formation of characteristic enlarged late endosomes and size of multivesicular bodies (MVBs)/lysosomes in HT1080 is directly dependent on Diaskedin. (A) Representative WB of total protein levels in WT, Diaskedin KO or Diaskedin KO cells, stably expressing WT HA‐tagged Diaskedin (Rescue). (B) Still images taken from live‐cell movies of WT and Diaskedin KO HT1080 cells, fed with fluorescently labeled DQBSA. Snapshots taken from movie S1. Scale bars: 10 μm. (C) Quantification of the percentage of WT, Diaskedin KO and Rescue cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between all genotypes (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Electron microscopy of cryofixed WT and Diaskedin KO HT1080 cells illustrating differences in size and morphology throughout all kinds of endo−/lysosomal compartments under steady state (arrows: MVBs; arrowheads: lysosomes; asterisks: enlarged late endosomes; m: mitochondria; n: nucleus). Scale bars: 2 μm. (E) Diameters of normal‐sized (≤700 nm) lysosomes and MVBs from WT, Diaskedin KO and Rescue HT1080 cell lines as measured by EM. At least 200 lysosomes or 120 MVBs, respectively, per genotype were measured. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between all genotypes (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (F‐I) Immunogold electron microscopy of Diaskedin KO cells, stably expressing HA‐tagged WT Diaskedin (Rescue). Anti‐HA label localizes predominantly at the limiting membrane of MVBs/late endosomes (F,G,H), lysosomes (I); Tokuyasu‐cryosection technique, scale bar: 200 nm
Formation of characteristic enlarged late endosomes and size of multivesicular bodies (MVBs)/lysosomes in HT1080 is directly dependent on Diaskedin. (A) Representative WB of total protein levels in WT, Diaskedin KO or Diaskedin KO cells, stably expressing WT HA‐tagged Diaskedin (Rescue). (B) Still images taken from live‐cell movies of WT and Diaskedin KO HT1080 cells, fed with fluorescently labeled DQBSA. Snapshots taken from movie S1. Scale bars: 10 μm. (C) Quantification of the percentage of WT, Diaskedin KO and Rescue cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between all genotypes (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Electron microscopy of cryofixed WT and Diaskedin KO HT1080 cells illustrating differences in size and morphology throughout all kinds of endo−/lysosomal compartments under steady state (arrows: MVBs; arrowheads: lysosomes; asterisks: enlarged late endosomes; m: mitochondria; n: nucleus). Scale bars: 2 μm. (E) Diameters of normal‐sized (≤700 nm) lysosomes and MVBs from WT, Diaskedin KO and Rescue HT1080 cell lines as measured by EM. At least 200 lysosomes or 120 MVBs, respectively, per genotype were measured. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between all genotypes (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (F‐I) Immunogold electron microscopy of Diaskedin KO cells, stably expressing HA‐tagged WT Diaskedin (Rescue). Anti‐HA label localizes predominantly at the limiting membrane of MVBs/late endosomes (F,G,H), lysosomes (I); Tokuyasu‐cryosection technique, scale bar: 200 nmBy applying high‐pressure freezing in combination with EM we determined alterations in size and morphology throughout the endocytic compartments in HT1080 WT and the corresponding Diaskedin KO cells under steady state conditions (Figure 2D). In WT cells lysosomes and multivesicular bodies were generally larger than in Diaskedin KOs (Figure 2D,E). Some WT cells also contained enlarged late endosomes (Figure 2D asterisks). These enlarged endosomes were excluded from ultrastructural morphometry and we focused on the precise measurements of normal‐sized organelles with diameters ranging from approximately 150 to 700 nm. Diaskedin KO cells were characterized by numerous small, dense lysosomes, that were rare in WT cells. In the Diaskedin deficient cell line, which re‐expressed HA‐Diaskedin, the size of late endosomes/lysosomes was similar to WT cells and the anti‐HA label localized predominantly at the limiting membrane of multivesicular bodies/late endosomes (Figure 2F‐H) and lysosomes (Figure 2I). Overall, these results suggested that Diaskedin localizes to late endosomes/lysosomes and controls their size and abundance.
Deletions of Diaskedin and Myrlysin but not Lyspersin abolish the formation of characteristic enlarged endosomes in HT1080
We next asked if other BORC components were also required to control the size of late endosomes/lysosomes similar to Diaskedin (Figure 2C and Figure 3A,B). Therefore, we also deleted Myrlysin, the membrane anchor of the BORC, and Lyspersin. In all three BORC mutants (Diaskedin, Myrlysin and Lyspersin), the small GTPase Arl8b mislocalized from late endosomes to the cytoplasm—a well described BORC deletion phenotype (Figure 3C). Deletion of Myrlysinalso reduced the number of enlarged late endosomes and phenocopied Diaskedin KO cells. Yet, Lyspersin deficient late endosomes/lysosomes were indistinguishable from their WT counterparts in this aspect (Figure 3A,B). Additionally, the amount of BORC components bound to membranes in the cell, was generally altered upon Diaskedin and Myrlysin but not Lyspersin deletion (Supplementary Figure S1D,E). This led us to conclude that the size of late endosomes/lysosomes was specifically controlled by Diaskedin and Myrlysin, but not to all BORC components alike and was independent of Arl8b. The enlarged late endosomes observed in HT1080 WT cells were reminiscent of endolysosomes17, 22 in cells treated with the lysosomotropic antimalarial drug chloroquine (CQ)22 that prevents endosomal acidification. HT1080 WT cells exposed to CQ for 2 hours displayed an increased number of enlarged late endosomes compared to control cells at steady state (Supplementary Figure S2A,B). This increase in size was suppressed by Diaskedin or Myrlysin deletion but not by Lyspersin deletion. Blocking the V‐ATPase with bafilomycin A had a comparable effect (Supplementary Figure S2C). Stimulation of macropinocytosis through phorbol 12‐myristate 13‐acetate (PMA) administration enhanced the formation of enlarged endosomes more efficiently in WT cells and was dependent on Diaskedin (Supplementary Figure S2C). Inhibition of mechanistic target of rapamycin (mTOR) through rapamycin treatment or amino acid starvation had no influence on the cell population with enlarged late endosomes (Supplementary Figure S2C). Taking these findings together, we concluded that Diaskedin and Myrlysin are required for the formation of enlarged late endosomes in HT1080 cells. Alternatively, they may negatively regulate clearance of these organelles via lysosomal reformation.
Figure 3
Reduction of characteristic enlarged late endosomes upon deletion of Diaskedin and Myrlysin but not Lyspersin in HT1080 cells. (A) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells, stained with the late endosomal marker LAMP1 (green) and the early endosomal marker EEA1 (red). Scale bars: 10um. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each KO and the WT control (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells, transiently transfected with Arl8b‐GFP (green) and costained with the late endosomal marker LAMP1 (red). Scale bars: 10um
Reduction of characteristic enlarged late endosomes upon deletion of Diaskedin and Myrlysin but not Lyspersin in HT1080 cells. (A) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells, stained with the late endosomal marker LAMP1 (green) and the early endosomal marker EEA1 (red). Scale bars: 10um. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each KO and the WT control (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells, transiently transfected with Arl8b‐GFP (green) and costained with the late endosomal marker LAMP1 (red). Scale bars: 10um
PI(3,5)P2 levels regulate late endosomal size downstream of BORC
Having established that specific BORC subunits are required to regulate late endosomal/lysosomal size, we sought out to characterize the underlying molecular mechanism. One candidate was size regulation via the phosphatidylinositol phosphate species PI(3,5)P2. PI(3,5)P2 is generated from phosphatidylinositol 3‐phosphate [PI(3)P] by the lipid kinase PIKfyve and has been linked to the regulation of endosomal size and number.17, 18, 23 The lipid kinase PIKfyve phosphorylates PI(3)P to generate PI(3,5)P2 on late endosomes/lysosomes. PI(3,5)P2 plays an important role in late endosomal biogenesis. The reduction of PI(3,5)P2 levels leads to the enlargement of late endosomes/lysosomes and contributes to a variety of diseases.18, 23, 24, 25 To address the link between BORC and PI(3,5)P2 levels on endosomal size regulation, we used two established inhibitors, which block PI(3,5)P2 production; either by directly inhibiting PIKfyve with YM201636, or by blocking the upstream production of PI(3)P with VPS34‐IN1 (Supplementary Figure S3A) and measured their effects on the frequency of enlarged late endosomes/lysosomes in HT1080 cells (Figure 4A,B). Both inhibitors increased the frequency of enlarged endosomes/lysosomes, with the effect of YM201636 being more specific to late endosomes/lysosomes, whereas VPS34‐IN1 also induced inflation of early endosomes (Figure 4A). Upon inhibition of PI(3,5)P2, almost all Diaskedin KO cells displayed enlarged endosomes, similar to WT cells under the same condition. Similar results were obtained in HeLa cells treated with the above described inhibitors for 1 hour, and subsequently washed and recovered in inhibitor free medium for 1 hour (Supplementary Figure S3B,C). Based on these results we speculated that loss of Diasekdin resulted in hyperactive PIKfyve, which generated higher PI(3,5)P2 levels leading to the reduction of late endosomal/lysosomal size.
Figure 4
Inhibition of PI(3,5)P2 synthesis induces the formation of characteristic enlarged late endosomes in HT1080 cells. (A) Confocal images of WT and Diaskedin KO HT1080 cells in steady state and treated with either 2.5uM VPS34IN or 800 nM YM201636 for 2 hours and stained with LAMP1 (green) and EEA1 (red). Scale bars: 10 μm. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes either untreated in steady state or with inhibitor treatments. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed for every genotype in the tested conditions (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) Comparison of the abundancy of the indicated PtdInsPs in WT and Diaskedin KO HT1080 cells labeled with 3H‐myo‐inositol. Data presented as normalized (to total PI) mean values ± SD. Unpaired Student's t test was performed between WT and Diaskedin KO for every PtdInsP species where a difference of over 1.5x‐fold (dotted line) was observed from at least three independent biological replicates (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Inhibition of PI(3,5)P2 synthesis induces the formation of characteristic enlarged late endosomes in HT1080 cells. (A) Confocal images of WT and Diaskedin KO HT1080 cells in steady state and treated with either 2.5uM VPS34IN or 800 nM YM201636 for 2 hours and stained with LAMP1 (green) and EEA1 (red). Scale bars: 10 μm. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes either untreated in steady state or with inhibitor treatments. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed for every genotype in the tested conditions (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) Comparison of the abundancy of the indicated PtdInsPs in WT and Diaskedin KO HT1080 cells labeled with 3H‐myo‐inositol. Data presented as normalized (to total PI) mean values ± SD. Unpaired Student's t test was performed between WT and Diaskedin KO for every PtdInsP species where a difference of over 1.5x‐fold (dotted line) was observed from at least three independent biological replicates (*P ≤ .05; **P ≤ .01; ***P ≤ .001)To directly test this idea, we determined the changes in phosphoinositides (PtdInsP) species in Diaskedin deficient HT1080 cells compared to their WT counterparts. Therefore, HT1080 cells were incubated with 3H‐myo‐inositol to label PtdInsPs, followed by lipid extraction and deacylation, and the amount of PtdInsP species was compared to total phosphatidylinositol by flow scintillation. Most of the major PtdInsP species were similar between the WT and Diaskedin KO cells (Figure 4C). However, levels of PI(3,5)P2 and/or PI(3,4)P2, which for technical reasons are difficult to separate from each other by high performance liquid chromatography (HPLC), were higher in Diaskedin KO compared to WT cells (Figure 4C). To discriminate between PI(3,5)P2 and PI(3,4)P2, additional experiments were performed. For this purpose, cells were pretreated with the PIKfyve inhibitorApilimod (Supplementary Figure S3A), which completely abolished the signal from this peak and caused subsequent accumulation of the precursor PI(3)P (Supplementary Figure S3,D). This indicated that the significant increase, detected in steady state cells, was indeed caused by an increase of PI(3,5)P2. Most importantly, these experiments indicated that Diaskedin deletion resulted in a higher PI(3,5)P2 production, which is indicative of an increased activity of PIKfyve—the only known lipid kinase to phosphorylate PI(3)P to PI(3,5)P2. Thus, the smaller size of endosomes in Diaskedin KO cells correlated with increased levels of PI(3,5)P2, suggesting an inhibitory role for the BORC complex toward PIKfyve activity and PI(3,5)P2 production.
Diaskedin KO enhances tubule formation and lysosomal reformation
PI(3,5)P2 can drive the reformation of terminal lysosomes from acidic, hydrolase‐active enlarged endolysosomes17 and thereby promotes lysosome fission to maintain lysosome size and number.18 Since PI(3,5)P2 levels were increased in Diaskedin KO cells, we assumed that excessive lysosomal reformation occurs in these cells. This would result in unrestrained tubule formation and/or fission from late endosomes/lysosomes, resulting in ongoing lysosomal reformation and ultimately leading to the formation of smaller late endosomes/lysosomes. To test our assumptions in live cells over time, we generated LAMP1‐NeonGreen expressing HeLa WT and Diaskedin KO cell lines and analyzed tubule formation from late endosomes/lysosomes using live‐cell STED microscopy (Movies S2 and S3). We were able to follow individual LAMP1‐NeonGreen positive endosomes for about 23 seconds. During this time, LAMP1‐NeonGreen positive endosomes in WT HeLa cells remained relatively stable in size and shape and only a small portion of them displayed emerging tubules (2.6% based on over 100 endosomes in the first frames of seven independent movies) (Figure 5A). In the Diaskedin KO HeLa cells, the diameter of LAMP1‐NeonGreen positive endosomes was smaller and they displayed repetitive tubulation events (10.3% based on over 100 endosomes in the first frames of seven independent movies), pointing to enhanced lysosomal reformation. Ultrastructural analysis using transmission electron microscopy (TEM) from high‐pressure frozen samples at steady state (Figure 5B,C) supported these data. Diaskedin KO HeLa cells displayed numerous elongated profiles of late endosomes/lysosomes consistent with tubule formation and/or fission. Similar morphological features were hardly detected in WT HeLa cells. From the analysis of cross sections of approximately 200 cells per genotype, we roughly estimated the frequency of these tubulation events: EM sections from WT cells showed in total three cells with one singular elongated organelle profile, as compared to 45 cells with numerous (>10) elongated/tubule forming organelles per cell in Diaskedin KO.
Figure 5
Diaskedin KO leads to hyperactivated tubule formation of late endosomes/lysosomes. (A) Still images from movies S2 and S3 depicting WT and Diaskedin KO HeLa cells, stably expressing LAMP1‐NeonGreen and imaged over a period of 23.5 seconds with a super resolution STED microscope. The indicated stars mark the frames in which tubules are emerging from late endosomes/lysosomes. Scale bars: 500 nm. (B) EM reveals in Diaskedin KO HeLa cells (right) observed at steady state numerous elongated profiles of late endosomes (arrows) and lysosomes (arrow‐heads) presumably reflecting tubule formation and/or fission; these features are almost completely missing in WT HeLa cells (left). Scale bars: 2 μm in overviews, 200 nm in inserts. (C) Diaskedin KO HeLa cells at steady state show in 80 nm‐ultrathin EM‐sections late endosomes, lysosomes and autophago(lyso)somes with snapshot profiles suggestive of tubule formation and/or fission, which resemble the patterns of AA/FBS starvation (see also Figure 10D). Scale bars: 200 nm
Diaskedin KO leads to hyperactivated tubule formation of late endosomes/lysosomes. (A) Still images from movies S2 and S3 depicting WT and Diaskedin KO HeLa cells, stably expressing LAMP1‐NeonGreen and imaged over a period of 23.5 seconds with a super resolution STED microscope. The indicated stars mark the frames in which tubules are emerging from late endosomes/lysosomes. Scale bars: 500 nm. (B) EM reveals in Diaskedin KO HeLa cells (right) observed at steady state numerous elongated profiles of late endosomes (arrows) and lysosomes (arrow‐heads) presumably reflecting tubule formation and/or fission; these features are almost completely missing in WT HeLa cells (left). Scale bars: 2 μm in overviews, 200 nm in inserts. (C) Diaskedin KO HeLa cells at steady state show in 80 nm‐ultrathin EM‐sections late endosomes, lysosomes and autophago(lyso)somes with snapshot profiles suggestive of tubule formation and/or fission, which resemble the patterns of AA/FBS starvation (see also Figure 10D). Scale bars: 200 nm
Figure 10
Increased baseline autophagy upon Diaskedin and Myrlysin deletion in HeLa cells. (A) WB analysis of WT, Diaskedin KO and Myrlysin KO HeLa cells, either under steady state or upon AA/FBS starvation for the indicated time points (h). (B) WB analysis of WT, Diaskedin KO and Myrlysin KO HeLa cells, either under steady state, upon 6 hours AA/FBS starvation or upon 6 hours AA/FBS starvation in the presence of the indicated chemical inhibitors. (C) IF of WT and Diaskedin KO HeLa cells, stained for endogenous autophagic marker LC3 either under steady state or upon the indicated time of AA/FBS starvation. Scale bars: 10 μm. (D) EM of cryofixed HeLa WT and Diaskedin KO cells at steady state, as compared to 6 hours AA/FBS starvation. In WT cells autophagosomes (white arrow‐heads) are very rare at steady state, but increase in number after starvation. However, Diaskedin KO cells contain numerous autophagosomes already at steady state, and even more after 6 hours AA/FBS starvation. Inserts show autophagosomes with distinct buds and tubes considered to characterize lysosomal reformation59 as a consequence of starvation. Scale bars: 2 μm in overviews, 200 nm in inserts. (E) Frequency of autophagosomes per 100 square‐micron cytoplasm in WT and Diaskedin KO HeLa as counted on EM images. Autophagosomes from over 25 cells per genotype were counted. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
In a complementary approach, transient inhibition and subsequent reactivation of PIKfyve was used to boost tubule formation and/or fission events in HT1080 cells. In this experimental setup, WT and Diaskedin KO HT1080 cells were first treated with YM201636, then the inhibitor was washed‐out and the cells left to recover in an inhibitor free medium. During the recovery phase, cells were high‐pressure‐frozen and analyzed by EM in combination with tomography. Under these extreme conditions, both cell lines displayed enhanced tubule formation of endolysomal compartments. However, the process was still enhanced in Diaskedin KO cells, with more, though smaller tubules appearing in the Diaskedin KO cells, compared with their WT counterparts (Movies S4 and S5). These experiments indicated that activation of PIKfyve and the resulting increase in PI(3,5)P2 levels in Diaskedin KO indeed translated into more unrestrained lysosomal reformation and fission, which ultimately led to the observed decrease of late endosomal size.
AMPK activity modulates BORC's control over endosomal size
Next, we examined how BORC coupled to lysosomal signaling to restrain lysosomal reformation via PIKfyve. Several signaling pathways are recruited to late endosomes/lysosomes, by the LAMTOR/Ragulator complex, including mitogen‐activated protein kinase (MAPK), AMP‐activated protein kinase (AMPK) and mTORC1.26, 27, 28, 29, 30, 31 So far there have been only few reports on how PIKfyve is regulated, but two major kinases, namely AMPK32 and AKT33 have been reported to phosphorylate and thereby activate PIKfyve. Diaskedin deletion mutants have intrinsically more active AMPK and ERK signaling under most growth conditions, whereas AKT and mTORC1 (pS6K, pS6) signaling were largely unchanged compared to WT cells (Supplementary Figure S4A). Hence in Diaskedin deficient cells, AMPK signaling from the putative BORC localization at late endosomes might lead to higher PIKfyve activation.To directly test how AMPK signaling might control late endosomal/lyosomal size, we generated a CRISPR/Cas9 mediated KO of the alpha subunit of AMPK in HT1080 cells (Figure 6A‐C). Upon AMPK deletion, significantly more cells displayed enlarged late endosomes, indicating that AMPK modulated this phenotype. Therefore, we next asked whether AMPK signaling could help to explain the function of Diaskedin and Myrlysin in endosomal size regulation via enhanced PIKfyve activity and the resulting increase in PI(3,5)P2. To address this assumption, we performed PtdInsP lipid measurements in all HT1080 BORC deficient cell lines either in steady state or upon the addition of the specific AMPK inhibitorDorsomorphin (Figure 6D). Here, we noticed that not only Diaskedin KO, but also deletion of the BORC‐anchor Myrlysin caused significant accumulation of PI(3,5)P2. Lyspersin mutants showed only a mild increase. Importantly, the increase in PI(3,5)P2 production in Diaskedin and Myrlysin deletion mutants could be significantly inhibited by the treatment of the cells with Dorsomorphin. Consistently, Diaskedin (Supplementary Figure S4A) and Myrlysin KOs had increased activation of AMPK, whereas Lyspersin deletion mutants did not (data not shown). Taken together, these experiments link the BORC subunits Diaskedin and Myrlysin to AMPK signaling, which in turn activates PIKfyve to regulate late endosomal/lysosomal size regulation via PI(3,5)P2 production.
Figure 6
Deletion of AMPK leads to increased formation of characteristic enlarged late endosomes in HT1080 cells. (A) IF of WT and AMPK KO (subunit Alpha) HT1080 cells, stained with the late endosomal marker LAMP1 (green) and the early endosomal marker EEA1 (red). Scale bars: 10 μm. (B) WB analysis of WT and AMPK KO HT1080 cells. (C) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) WT and AMPK KO HT1080 cells were incubated with 3H‐myo‐ inositol and the indicated PtdInsP species and their abundancy was compared in either steady state or upon Dorsomorphin addition. Data presented as normalized (to total PI) mean values ± SD. Unpaired Student's t test was performed between WT and Diaskedin KO for every PtdInsP species where a difference of over 1.5x‐fold (dotted line) was observed from at least three independent biological replicates (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Deletion of AMPK leads to increased formation of characteristic enlarged late endosomes in HT1080 cells. (A) IF of WT and AMPK KO (subunit Alpha) HT1080 cells, stained with the late endosomal marker LAMP1 (green) and the early endosomal marker EEA1 (red). Scale bars: 10 μm. (B) WB analysis of WT and AMPK KO HT1080 cells. (C) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes. Cells were counted from at least three biological replicates with over 100 cells per genotype pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) WT and AMPK KO HT1080 cells were incubated with 3H‐myo‐ inositol and the indicated PtdInsP species and their abundancy was compared in either steady state or upon Dorsomorphin addition. Data presented as normalized (to total PI) mean values ± SD. Unpaired Student's t test was performed between WT and Diaskedin KO for every PtdInsP species where a difference of over 1.5x‐fold (dotted line) was observed from at least three independent biological replicates (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Contribution of the LAMTOR/Ragulator complex
The LAMTOR/Ragulator complex is a major player in the regulation of late endosomal/lysosomal signaling as it recruits and facilitates MAPK, AMPK and mTORC1 activation on late endosomes/lysosomes.30, 34 Since BORC and the LAMTOR/Ragulator complex interact on late endosomes/lysosomes,14, 15 we addressed how their interaction contributed to endosomal size regulation. Therefore, we generated CRISPR/Cas9 KO cells of Diaskedin in mouse embryonic fibroblasts (MEFs) bearing either a single WT allele (f/−, control) or complete LAMTOR2 deletion (−/−, LAMTOR2KO) as previously established27 (Figure 7A). Deletion of LAMTOR2 is sufficient to cause a rapid disassembly and degradation of the entire LAMTOR complex.14, 35 By high‐pressure freezing in combination with EM, we performed extensive morphometry analysis of late endosomal/lysosomal compartments in these MEFs (Figure 7B,C). MEFs bearing a Diaskedin deletion had significantly smaller lysosomes compared to their control counterparts and clustered in the perinuclear region (Figure 7B,C). Hence, loss of Diaskedin triggered the formation of smaller late endosomes/lysosomes in HeLa (Figure 1), HT1080 (Figure 2) and in MEF cells (Figure 7). Consistent with our previous observations, late endosomes/lysosomes in LAMTOR2 deficient MEFs were translocated toward the periphery of the cell27 and were also smaller,36 albeit the significant size reduction was not as dramatic as in Diaskedin deletion mutants. When both LAMTOR2 and Diaskedin were deleted (ie, Double KO), late endosomes/lysosomes were clustered in the perinuclear region and their size was significantly smaller than in any of the single KO MEFs or WT cells (Figure 7B,C), indicating an additive effect of BORC and its interacting LAMTOR/Ragulator complex in endosomal size regulation.
Figure 7
Endosomal phenotypes in LAMTOR/Ragulator KO, BORC KO and LAMTOR/Ragulator‐BORC Double KO MEFs. (A) Representative WB of total protein levels in WT (LAMTOR2 f/−), LAMTOR2 KO (−/−), Diaskedin KO and Double KO MEFs (LAMTOR2 −/− MEFs subjected to Diaskedin KO). (B) WT MEFs (LAMTOR2 f/−) show a canonical phenotype regarding lysosomal size and distribution. By contrast, LAMTOR2 KO (−/−) MEFs contain smaller lysosomes, most of which are typically translocated to the cell periphery. Diaskedin KO MEFs are characterized by perinuclear clustering of lysosomes that are even smaller than those of LAMTOR2 KO (−/−) MEFs. Double KO MEFs, (LAMTOR2 −/− MEFs subjected to Diaskedin KO), also show distinct perinuclear clustering of lysosomes, that are again clearly smaller than those of the other MEF lines investigated here. Arrows mark the sites of the (partly rotated/mirrored) inserts. Scale bars: 2 μm in overviews, 1 μm in inserts (n: nucleus). (C) Lysosomal diameters in the indicated MEF cell lines as measured on EM images. Over 600 lysosomes from over 25 cells per genotype were measured. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed for every genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Endosomal phenotypes in LAMTOR/Ragulator KO, BORC KO and LAMTOR/Ragulator‐BORC Double KO MEFs. (A) Representative WB of total protein levels in WT (LAMTOR2 f/−), LAMTOR2 KO (−/−), Diaskedin KO and Double KO MEFs (LAMTOR2 −/− MEFs subjected to Diaskedin KO). (B) WT MEFs (LAMTOR2 f/−) show a canonical phenotype regarding lysosomal size and distribution. By contrast, LAMTOR2 KO (−/−) MEFs contain smaller lysosomes, most of which are typically translocated to the cell periphery. Diaskedin KO MEFs are characterized by perinuclear clustering of lysosomes that are even smaller than those of LAMTOR2 KO (−/−) MEFs. Double KO MEFs, (LAMTOR2 −/− MEFs subjected to Diaskedin KO), also show distinct perinuclear clustering of lysosomes, that are again clearly smaller than those of the other MEF lines investigated here. Arrows mark the sites of the (partly rotated/mirrored) inserts. Scale bars: 2 μm in overviews, 1 μm in inserts (n: nucleus). (C) Lysosomal diameters in the indicated MEF cell lines as measured on EM images. Over 600 lysosomes from over 25 cells per genotype were measured. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed for every genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Reduction of endosomal size upon glucose starvation
AMPK is a major sensor of the cellular energy status in eukaryotic cells,37 responding to low energy status by switching off anabolic pathways and upregulating catabolic processes. Recently, it was demonstrated that different intensities of AMPK stimulation trigger activation of specific subcellular pools, resulting in phosphorylation of distinct downstream targets. Under conditions of glucose starvation that do not elevate cellular adenosine monophosphate: ADP or adenosine diphosphate:ATPratios, only lysosomal AMPK is activated and exclusively through the lysosomal pathway.38Therefore, we next tested if the activation of AMPK by glucose starvation would also affect endosomal size. Therefore, we starved HT1080 WT, Diaskedin KO, Myrlysin KO and Lyspersin KO cells for glucose19, 30 and analyzed the percentage of cells with enlarged endosomes (Figure 8A,B). Much like the Diaskedin deletion mutant, which has intrinsically higher levels of AMPK signaling (Supplementary Figure S4A) and smaller late endosomes/lysosomes (Figure 2), glucose‐starved WT HT1080 now also reduced enlarged late endosomes, compared to nonstarved controls. This phenotype was quickly reverted when cells were placed back in high glucose containing medium (Figure 8A,C). Glucose starvation caused an increase in pAMPK in WT HT1080 cells, which was exacerbated upon Diaskedin deletion (Figure 8D). Upon glucose restimulation, pAMPK levels decreased again (Figure 8D). When cells were treated with the AMPK inhibitorDorsomorphin in combination with glucose starvation, there was a prominent increase of the number of cells that displayed enlarged late endosomes (Figure 8A,C). The increase in cells, bearing characteristic enlarged late endosomes, upon AMPK inhibition by Dorsomorphin was also observed in HT1080 WT and Diaskedin KO cells under full growth conditions (Supplementary Figure S4B,C). Here, we treated cells with the chemical inhibitors Dorsomorphin and PD0325901, which either block AMPK or MAPK signaling, respectively, and scored for the percentage of cells that displayed enlarged late endosomes. When incubating WT and Diaskedin KO cells with Dorsomorphin, we noticed a significant increase of the number of cells with enlarged late endosomes in both genotypes, compared to steady state cells (Supplementary Figure S4B,C). On the contrary, upon using the MEK inhibitorPD0325901 we saw the opposite, with clearly less cells showing enlarged endosomes, particularly in the WT genotype (Supplementary Figure S4B,C). This reciprocal effect of the two inhibitors used, could be explained by the fact that AMPK and MAPK signaling have been demonstrated to have a reciprocal negative effect on each other.39 Indeed, when total cell lysates of Dorsomorphin‐ or PD0325901‐treated cells were analyzed by Western blotting for pERK or pACC, as direct targets for either MAPK or AMPK activity, respectively, this effect could be recapitulated (Supplementary Figure S4D). Cells, treated with Dorsomorphin had decreased activity of AMPK compared with cells in steady state, but displayed hyperactivated MAPK signaling and vice versa: cells treated with PD0325901 had an almost complete block of MAPK signaling, but hyperactivated AMPK. Importantly, Diaskedin KO HT1080 cells showed consistent increase of pACC, further supporting our observation that these cells have intrinsically increased AMPK signaling. Taken together, glucose starvation as a trigger for AMPK activation reduced late endosomal/lysosomal size, possibly by controlling PIKfyve dependent PI(3,5)P2 levels and lysosomal reformation.
Figure 8
Reduction of characteristic enlarged late endosomes in HT1080 cells upon energy stress. (A) Confocal images of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells in steady state or upon 12 hours glucose starvation. Additionally, WT and Diaskedin KO HT1080 cells were restimulated after the starvation for 3 hours with glucose containing medium or starved for 12 hours for glucose in the presence of Dorsomorphin. Cells were stained with LAMP1 (green) and EEA1 (red). Scale bars: 10 μm. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes in steady state or upon 12 hours glucose starvation. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes in steady state, upon 12 hours glucose starvation, 12 hours glucose starvation followed by 3 hours glucose restimulation and upon 12 hours glucose starvation in the presence of Dorsomorphin. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Representative WB of WT and Diaskedin KO HT1080 cells either in steady state, upon 12 hours glucose starvation and 12 hours glucose starvation followed by 3 hours glucose restimulation
Reduction of characteristic enlarged late endosomes in HT1080 cells upon energy stress. (A) Confocal images of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HT1080 cells in steady state or upon 12 hours glucose starvation. Additionally, WT and Diaskedin KO HT1080 cells were restimulated after the starvation for 3 hours with glucose containing medium or starved for 12 hours for glucose in the presence of Dorsomorphin. Cells were stained with LAMP1 (green) and EEA1 (red). Scale bars: 10 μm. (B) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes in steady state or upon 12 hours glucose starvation. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (C) Quantification of the percentage of cells that display HT1080 characteristic enlarged late endosomes in steady state, upon 12 hours glucose starvation, 12 hours glucose starvation followed by 3 hours glucose restimulation and upon 12 hours glucose starvation in the presence of Dorsomorphin. Cells were counted from at least three biological replicates with over 100 cells per genotype and tested condition pro replica. Data presented as mean values ± SD. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001). (D) Representative WB of WT and Diaskedin KO HT1080 cells either in steady state, upon 12 hours glucose starvation and 12 hours glucose starvation followed by 3 hours glucose restimulation
Enhanced lysosomal reformation correlates with autophagy induction in BORC deficient cells
Having established that lysosomal biogenesis was severely altered upon deletion of core BORC components, we next investigated whether this would also affect autophagy, since lysosomal reformation and autophagy are tightly interconnected and depend on each other.40 The lysosomal calcium channel Mucolipin‐1 (ML‐1), also known as TRPML1 (transient receptor potential cation channel, Mucolipin subfamily, member 1), has been shown to be required for proper TFEB dephosphorylation and thus TFEB translocation into the nucleus, which consequently is a prerequisite for autophagy initiation. Interestingly, ML‐1 activation is dependent on PI(3,5)P2 levels on lysosomes.41, 42 This led us to the hypothesis that increased PI(3,5)P2 production, observed in Diaskedin and Myrlysin deletion mutants and the resulting higher ML‐1 activation, would translate into more dephosphorylation and thus activation with subsequent nuclear accumulation of TFEB. Indeed, under normal feeding conditions, Diaskedin and Myrlysin depleted HeLa cells displayed significantly higher nuclear TFEB localization, compared to WT and Lyspersin KO cells (Figure 9A,B) and this effect could be mimicked by treating cells with a synthetic Mucolipin‐1 activator (ML‐SA1).43 Under starvation conditions all four genotypes displayed similar high nuclear TFEB localization. The stronger nuclear TFEB signal in Diaskedin and Myrlysin deletion mutants (Figure 9A,B) would be suggestive of increased baseline autophagy. To test this assumption, we analyzed the lipidation status of the autophagy marker LC3 (microtubule‐associated proteins 1A/1B light chain 3B).44 Under steady state, Diaskedin and Myrlysin deletion mutants had higher levels of lipidated LC3 compared to WT, indicative of active autophagy (Figure 10A,C). Over a 6 hours AA and fetal bovine serum (FBS) starvation time course the levels of lipidated LC3 were reduced, presumably because of LC3 consumption in lysosomes (Figure 10A,C). When the lysosomal inhibitors Bafilomycin A or CQ were added in combination with 6 hours AA and FBS starvation, lipidated LC3 became less efficiently degraded and accumulated to comparable amounts in all genotypes (Figure 10B). EM analysis after high pressure freezing of WT and Diaskedin KO HeLa cells under steady state and upon 6 hours AA and FBS starvation allowed us to visualize and count autophagosomes in these cells (Figure 10D,E). Importantly, Diaskedin KO cells had consistently more autophagosomes already at steady state and those numbers increased further during starvation, corroborating our hypothesis that these cells display increased baseline autophagy.
Figure 9
Increased nuclear TFEB translocation upon Diaskedin and Myrlysin but not Lyspersin deletion in HeLa cells. (A) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HeLa cells, stained for endogenous TFEB (green) and the nuclear marker DAPI (blue) either under normal feeding (fed) condition, under fed condition in the addition of 10 μM ML‐SA1 or upon 3 hours AA and FBS starvation. Scale bars: 10um. (B) Quantification of the TFEB‐DAPI colocalization, based on at least 10 frames, acquired from two biological replicates in each corresponding genotype and condition. Data presented as mean values ± SD. Unpaired Student's t test was performed between each genotype pro condition (*P ≤ .05; **P ≤ .01; ***P ≤ .001)
Increased nuclear TFEB translocation upon Diaskedin and Myrlysin but not Lyspersin deletion in HeLa cells. (A) IF of WT, Diaskedin KO, Myrlysin KO and Lyspersin KO HeLa cells, stained for endogenous TFEB (green) and the nuclear marker DAPI (blue) either under normal feeding (fed) condition, under fed condition in the addition of 10 μM ML‐SA1 or upon 3 hours AA and FBS starvation. Scale bars: 10um. (B) Quantification of the TFEB‐DAPI colocalization, based on at least 10 frames, acquired from two biological replicates in each corresponding genotype and condition. Data presented as mean values ± SD. Unpaired Student's t test was performed between each genotype pro condition (*P ≤ .05; **P ≤ .01; ***P ≤ .001)Increased baseline autophagy upon Diaskedin and Myrlysin deletion in HeLa cells. (A) WB analysis of WT, Diaskedin KO and Myrlysin KO HeLa cells, either under steady state or upon AA/FBS starvation for the indicated time points (h). (B) WB analysis of WT, Diaskedin KO and Myrlysin KO HeLa cells, either under steady state, upon 6 hours AA/FBS starvation or upon 6 hours AA/FBS starvation in the presence of the indicated chemical inhibitors. (C) IF of WT and Diaskedin KO HeLa cells, stained for endogenous autophagic marker LC3 either under steady state or upon the indicated time of AA/FBS starvation. Scale bars: 10 μm. (D) EM of cryofixed HeLa WT and Diaskedin KO cells at steady state, as compared to 6 hours AA/FBS starvation. In WT cells autophagosomes (white arrow‐heads) are very rare at steady state, but increase in number after starvation. However, Diaskedin KO cells contain numerous autophagosomes already at steady state, and even more after 6 hours AA/FBS starvation. Inserts show autophagosomes with distinct buds and tubes considered to characterize lysosomal reformation59 as a consequence of starvation. Scale bars: 2 μm in overviews, 200 nm in inserts. (E) Frequency of autophagosomes per 100 square‐micron cytoplasm in WT and Diaskedin KO HeLa as counted on EM images. Autophagosomes from over 25 cells per genotype were counted. Data presented as median value with the box representing the 25th and 75th percentile, and the whiskers—the minimal and maximal values. Unpaired Student's t test was performed between each condition in each genotype (*P ≤ .05; **P ≤ .01; ***P ≤ .001)We concluded that deletion of the two BORC subunits Diaskedin and Myrlysin resulted in hyperaction of AMPK, which in turn activated PIKfyve. Higher levels of PI(3,5)P2 enforced ML‐1 dependent transcription factor (TFEB) activation, initiated autophagy and enhanced lysosomal reformation. As these processes are no longer restrained by BORC, this ultimately led to shrinking and increasing number of lysosomes.
DISCUSSION
BORC regulates late endosomal/lysosomal size via PI(3,5)P2
The multimeric BORC localizes to the limiting membrane of late endosomes/lysosomes and controls organelle positioning, through the recruitment of the small Arf‐like GTPase Arl8b2. All components of the BORC complex investigated (Diaskedin, Myrlysin and Lyspersin), contribute to the same extent to endosomal positioning through Arl8b recruitment (Figure 3C).14, 15 In the present contribution, we have shown that two BORC subunits, Diaskedin and Myrlysin exerted an additional effect on endosomal size via PI(3,5)P2. Cells, bearing those specific BORC deletions have elevated PI(3,5)P2 levels and in consequence contained more and smaller late endosomes/lysosomes. Interestingly, this phenotype was not equally shared by Lyspersin deletion mutants. Based on our results, we propose that the BORC components Diaskedin and Myrlysin fulfill a so far unexplored function in endosomal size regulation, in addition to their contribution to Arl8b recruitment and endosomal positioning.In particular, we found that members of the BORC complex negatively regulate PIKfyve activity and thereby affect PI(3,5)P2 levels and consequently late endosomal/lysosomal size. The direct quantification of PtdInsP species revealed that PI(3,5)P2 was highly enriched in Diaskedin KO cells (Figure 4C and Supplementary Figure S3D). This could be caused either by activating the lipid kinase PIKfyve or by inhibiting the counteracting phosphatase Sac3. As both the kinase and the phosphatase reside within the same conserved protein PIKfyve‐ArPIKfyve‐Sac3 (PAS) complex,45, 46, 47 future studies should resolve in detail how exactly BORC interfaces with the PIKfyve containing PAS complex to regulate PI(3,5)P2 production. Based on our results, we propose a model in which enhanced PI(3,5)P2 production leads to more active lysosomal reformation and/or fission, which has recently been linked to PIKfyve activity.17, 18 Therefore, cells bearing a Diaskedin deletion, undergo too frequently lysosomal fission and reformation. Therefore, these cells have (a) smaller and (b) more late endosomes.Furthermore, our results suggest that AMPK functions as a possible activator of PIKfyve in PI(3,5)P2 synthesis, driving endosomal reformation and thus leading to reduction of endosomal size. This conclusion is based on several independent observations. First, AMPK KO in HT1080 cells led to increased numbers of characteristic enlarged endosomes (Figure 6A‐C). Concomitantly, Dorsomorphin‐mediated inhibition of AMPK led to reduced PI(3,5)P2 production (Figure 6D) and simultaneously to an increase in the frequency of enlarged endosomes in HT1080 cells (Figure 8A,C and Supplementary Figure S4B,C). Conversely, AMPK activation by means of glucose starvation had the opposite effect and characteristic, enlarged late endosomes of HT1080 cells were dramatically reduced (Figure 8). As AMPK has been shown to directly phosphorylate the sole PI(3,5)P2 producing kinase PIKfyve,32 we envision that the observed increase in PI(3,5)P2 in Diaskedin KO HT1080 (Figure 4C and Supplementary Figure S3D) is caused by the intrinsic increase of AMPK activity in these cells (Supplementary Figure S4A,D). In light of these findings, we tested whether altered PI(3,5)P2 levels would vice versa have an effect on the BORC complex. For this we incubated WT HeLa cells with the previously described PI(3,5)P2 inhibitors VPS34IN and YM201636 (Supplementary Figure S3A) and performed subcellular fractionation to detect possible changes in BORC expression and localization. Based on the observation that inhibition of PI(3,5)P2 by those inhibitors led to the decrease of BORC components specifically at membrane fractions (Supplementary Figure S5A,B), it is tempting to speculate that PI(3,5)P2 levels could regulate BORC stability and/or localization in a feedback mechanism and thereby ultimately control lysosomal reformation and late endosomal/lysosomal size reduction.
Glucose levels regulate late endosomal/lysosomal size
When subjected to energy stress, cells react by reprogramming anabolic and catabolic processes, favoring the latter to maintain cellular homeostasis and to survive stress conditions. The endolysosomal system is a main regulator of those processes with a central role for the lysosomal residential LAMTOR/Ragulator complex in sensing intracellular AA and glucose levels and subsequent lysosomal mTORC1 activation.28, 29, 48 Based on our work, we propose that components of the BORC complex fulfill additional functions, which are linked to LAMTOR/Ragulator. Previously we identified a LAMTOR/Ragulator deletion phenotype, which is manifested by an increased number and also decreased size of late endosomes/lysosomes.36 Here, we describe that LAMTOR/Ragulator interacting BORC components could be responsible for the observed phenotype. In our epistasis experiments (Figure 7), where late endosomal/lysosomal size was taken as a readout, LAMTOR/Ragulator deletion highly phenocopied BORC deletion, albeit to a lesser extent. Importantly, when the BORC core component Diaskedin was deleted in LAMTOR2 deficient cells (double KO), there was a further decrease of late endosomal/lysosomal size. This could indicate that primarily components of the BORC complex are responsible for the regulation of late endosomal/lysosomal size and LAMTOR/Ragulator fulfills modulating functions. Alternatively, since LAMTOR and BORC display a synthetic/synergistic phenotype on late endosomal/lysosomal size, this could indicate that BORC and LAMTOR function in two parallel pathways that control late endosomal/lysosomal size independently. In contrast, for the distribution of late endosomes, it is clear that BORC is upstream of LAMTOR and that both complexes work together to position late endosome/lysosomes. Deletion of LAMTOR/Ragulator is associated with translocation of late endosomes/lysosomes toward the cell periphery.27 Notably, this distinct mislocalization phenotype was dependent on BORC (Figure 7B).In our current work, we demonstrated that energy stress, triggered by glucose deprivation, is accompanied by significant morphological changes of the endolysosomal system, in particular size reduction of late endosomes/lysosomes. This is most likely achieved by inducing lysosomal reformation via PIKfyve activation and subsequent PI(3,5)P2 production and could have several beneficial effects for the cell. For instance, autophagy, a process which is also boosted during glucose starvation, requires newly formed lysosomes to efficiently degrade cargo molecules and thereby recycle metabolic building blocks on which cells rely during nutrient shortage. Surprisingly, the acute morphological changes in the endolysosomal system following glucose limitation were reminiscent of Diaskedin deletion (Figure 8A,B). Accordingly, late endosomes/lysosomes of Diaskedin KO cells appeared to be constantly undergoing lysosomal reformation, even when not under starvation stress. Therefore, we propose that the BORC might participate in an energy sensing machinery, which ultimately affects endosomal size and morphology.Recently Zong and colleagues suggested that glucose sensing by the lysosomal AMPK activation pathway serves as a surveillance system monitoring the availability of glucose and switching off anabolic pathways.38 Our data might provide a link for the lysosomal noncanonical glucose‐sensing role of AMPK30 toward the executing BORC machinery for late endosomal/lysosomal adaption. We propose a model (Supplementary Figure S5C) in which low energy levels, caused for instance by glucose starvation, activate lysosomal reformation via the “BORC‐AMPK‐PIKfyve‐ML‐1 axis.” BORC is embedded in regulatory circuitry involving AMPK, PIKfyve, ML‐1, TFEB and autophagy. Activating one of those players could potentially set in motion an entire feed‐forward feedback mechanism. Upon glucose restimulation, BORC is then required to limit lysosomal reformation by negatively regulating AMPK‐dependent PIKfyve activation. In Diaskedin deletion mutants, this process is no longer restricted and might lead to a constant energy stress‐like status, which is manifested by activated AMPK signaling and subsequently increased PIKfyve activity and lysosomal reformation. Furthermore, constant energy stress‐like status also leads to increased baseline autophagy, which we observed in Diaskedin KO and Myrlysin KO cell lines. While TFEB dephosphorylation and its subsequent nuclear translocation can promote autophagy, it also promotes lysosomal biogenesis including regulation of LAMP1 levels, which might explain why some BORC deletion mutants display higher LAMP1 levels (Figure 1A, 2A and Supplementary Figure S1D). This is manifested by increased autophagosome generation and we believe that it is functionally linked to tubule formation and the resulting reduction of endosomal size (Supplementary Figure S5C). Both endosomal/lysosomal size regulation and tubule formation as well as baseline autophagy are themselves dependent on PI(3,5)P2 production, which we demonstrated to be controlled by the activity of BORC, the LAMTOR/Ragulator and AMPK complexes. Defects in PI(3,5)P2 synthesis have been linked to a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Charcot‐Marie‐Tooth (CMT) disease.49, 50, 51 Lysosome reformation may occur in one of two processes: (a) as part of the baseline lysosome‐endosome fusion‐fission cycles and (b) reformation from spent autolysosomes as in ALS. Therefore, one could envision the findings presented here as a basis for exploring possibilities to treat such conditions.Note added in proof: Recent work by others provided complementary insight into the impact of PIKfyve on endolysosomal homeostasis (Sharma G, Guardia CM, Roy A, et al. A family of PIKFYVE inhibitors with therapeutic potential against autophagy‐dependent cancer cells disrupt multiple events in lysosome homeostasis. Autophagy. 2019:1‐25.).
The pLentiCRISPRv2‐LoxPv1 plasmid was generated by inserting LoxP sites (5′ATAACTTCGTATAGCATACATTATACGAAGTTAT‐3′) flanking the elongation factor 1α short (EFS) promotor of the pLentiCRISPRv2 plasmid (Addgene 5261).52 Guide RNA (gRNA) sequences targeting Homo sapiensDiaskedin (5′‐GGTTCGGTCAGTCCGTGAAG‐3′), (myrlysin) (5′‐CCGATATCAAGATCACCTGC‐3′), lyspersin(5′‐GCGTCGTCCACCGGCCGGAA‐3′), PRKAA1(5′‐CCGAGAAGCAGAAACACGA‐3′) and Mus musculusDiaskedin(5′‐GATTTGGTCAGTCCGTGAAG‐3′) were selected, based on the online gRNA prediction tool (http://crispr.mit.edu/).53 The gRNAs were subsequently subcloned in pLentiCRISPRv2‐LoxPv1 and used for lentiviral production. For production of lentivirus containing the CRISPR/Cas9 and the selected gRNAs, HEK293LTV cells were used. These were cotransfected with pLentiCRISPRv2‐LoxPv1, containing a single gRNA together with pVSV‐G (Clonetech 631 530) and psPAX2. The supernatant was used to directly infect target cells, which were subsequently selected with 1ug/mL puromycin (Sigma P7255). HT1080 Lyspersin KOs, HT1080 Myrlysin KOs, HT1080 LAMTOR2 KOs and HT1080 Double KOs (Diaskedin and LAMTOR2) were used as “bulk” KO. For the generation of the HT1080 Diaskedin KOs and the HeLa Diaskedin KOs, the cells were further transiently transfected with pCAG‐Cre‐GFP (Addgene 13 776) to remove the Cas9 and fluorescence‐activated cell sorting (FACS) sorted to enrich for the GFP positive population, expressing high Cre amounts. These were then allowed to recover for 24‐48 hours before they were seeded at a concentration below 5cells/mL in 200 μL in 96well plates. The single cell clones were tested by a polymerase chain reaction (PCR) screen54 and by Western blotting for the loss of the target gene.
Plasmid generation
The template for generating a rescue HA‐Diaskedin construct was generated by reverse transcription and complementary deoxyribonucleic acid synthesis from messanger ribonucleic acid extracts from HT1080WT cells. Two specific digestion sites (NotI and XbaI) were introduced, flanking the open reading frame (ORF) of Diaskedin. These were then used to insert Diaskedin ORF into pENTR4 (Invitrogen A10465), bearing an N‐terminal HA‐tag. The construct was recombined, using a GATEWAY LR reaction (Invitrogen), into pCCL‐EFS‐Blasti‐DEST mammalian expression vector. Similarly, a C‐terminally tagged version of Myrlysin was generated, using specific digestion sites (NcoI and BamHI) on pENTR4 (Invitrogen A10465) vector, bearing a C‐terminal Ruby tag. This was then recombined, using a GATEWAY LR reaction (Invitrogen), into pCCL‐EF1Alpha‐DEST mammalian expression vector. A full length Arl8b was cloned into pENTR207 (Invitrogen 12213‐013) vector, excluding the stop codon. This was then shuttled to pEGFP‐N‐DEST vector using GATEWAY technology (Invitrogen). pEGFP‐N‐DEST was itself generated from pEGFP‐C1 (Clontech), modified by inserting a GATEWAY destination cassette (Invitrogen) into the NheI site upstream of the enhanced green fluorescent protein coding sequence. The generation of LAMP1‐Neon Green was performed as follows: full‐length ratLAMP1—fused to mNEONGreen (Allele Biotech, San Diego, USA) was amplified by PCR, subcloned into BamH1‐NotI sites of pENTR4 (Invitrogen A10465) and then shuttled to pQXCIN‐DEST using GATEWAY technology (InVitrogen). pQXCIN itself was generated from pQCXIN (Clontech), modified into a GATEWAY compatible destination vector by inserting a GATEWAY destination cassette into the AgeI site upstream of the IRES‐NEO cassette. G glycoprotein of vesicular stomatitis virus (VSV‐G) pseudotyped retroviral virions were generated by transient transfection of amphotropic Phoenix packaging cells55 and used to infect target cells. Transduced cells were selected against 1 mg/mL G418.
Subcellular fractionation
Cells grown on 15 cm petri dishes were cooled on metal plates on ice and washed with ice cold phosphate buffer saline (PBS). PBS, containing 0.5x protease inhibitors was added and cells were scraped, transferred to Falcon tubes and centrifuged in a precooled centrifuge at 160g for 5 minutes. The supernatant was removed and the pellet wash washed (without disturbing its integrity) with Homogenization Buffer (250 mM sucrose and 3 mM imidazole in H2O), supplemented with 1 mM ethylenediaminetetraacetic acid (EDTA), 30ug/mL cycloheximide and 1x protease inhibitors (HB+ buffer). Upon another centrifugation step at 690g for 10 minutes, the supernatant was removed and cells were completely resuspended in HB+ buffer, using three times the volume of the pellet. Cells were then homogenized using a 25‐G needle, attached to a 1 mL syringe. Nuclei were pelleted at 1000g for 10 minutes. The postnuclei supernatant (PNS) was further centrifuged at 100000g; the supernatant was collected as cytosolic fraction and the pellet was resuspended in equal volume homogenization buffer and labeled as total membranes. For the isolation of crude endosomal (CE) fraction, PNS was loaded on the bottom of SW41 centrifuge tubes (Beckman Coulter). The sucrose concentration of the PNS fraction was adjusted to 40.6% by adding about 1.2x the volume of the PNS of 62% sucrose. The mixture was overlaid with 7‐8 mL of 35% sucrose (supplemented with protease inhibitors and cycloheximide). The last few millimeters of the tube were filled with homogenization buffer, supplemented with protease inhibitors. The samples were centrifuged for 3 hours at 34 000 rpm at 4°C in a Beckman Coulter ultracentrifuge, using SW41 rotor. Upon centrifugation, 750 μL of the upper fraction was collected, 500ul of 3 mM Imidazole (pH 7.4) was added and centrifuged again for 30 minutes at 100 000g at 4°C. The supernatant was discarded and the pellet was resuspended in 30ul homogenization buffer containing protease inhibitors and labeled as CEs.
Cell culture
Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with high glucose (SIGMA D6429) or alternatively for glucose starvation in DMEM without glucose (Thermo Fischer Scientific 11966025), supplemented with 10% FBS (Gibco 10 270) and 100 U/mL penicillin and 100 mg/mL streptomycin (SIGMA P0781) at 37°C, in 5% CO2 and 95% humidity. For trypsination of the cells, a Trypsin‐ EDTA solution (SIGMA T4174) and homemade PBS was used. Stable cell lines, expressing HA‐Diaskedin (Rescue) were supplemented with 10 μg/mL blasticidin and “bulk” KO cell lines were selected in media containing 1 μg/mL Puromycin.
Immunofluorescence and live cell microscopy
Cells, grown on glass cover slips, were fixed in 4% formaldehyde solution in PBS for 10 minutes and subsequently washed with PBS. The cells were then permeabilized in blocking buffer (0.05% saponin in PBS with 10% goat serum [SIGMA G6767]) for 1 hour at room temperature (RT); incubated for 1 hour at RT with primary antibodies, diluted in blocking buffer; washed several times with PBS; incubated for further 1 hour at RT with secondary antibodies, diluted in blocking buffer; washed once briefly with PBS containing 4′,6‐diamidino‐2‐phenylindole; washed several more times with PBS and mounted on microscope slides using Mowiol. Alternatively, cells were permeabilized in 0.2% Triton in PBS for 5 minutes and no detergents were used in the subsequent steps. Still images were acquired on the Axio‐Imager M1 microscope (Carl Zeiss) with a 100x oil immersion objective (NA 1.45), equipped with a SPOT Xplorer, Visitron Systems camera at RT and movies on an inverted Zeiss Axiovert 200 M microscope with a 63x oil immersion objective (NA 1.4), equipped with Cool SNAP HQ2 Photonics interline CCD camera in a 37°C heated chamber using Leibovitz's phenol free medium (Invitrogen 21083‐027). Acquisition was controlled by VisiView software (Visitron Systems GmbH). Single plane confocal images and Z stacks were acquired using a Laser Scanning Confocal Microscope (SP5, Leica) with a 63x oil immersion objective (NA 1.4) at RT. For super resolution imaging a gated STED with a pulsed white light laser (SP8 gSTED, Leica) microscope with a 63x oil immersion objective (NA 1.4) was used. Still images were acquired at RT and movies in a 37°C heated chamber using Leibovitz's phenol free medium (Invitrogen 21083‐027). Still images and movies, acquired at the SP8 gSTED, were deconvoluted with Huygens Professional Deconvolution and Analysis Software (Scientific Volume Imaging). All images were reformatted to TIFF (respectively time series to movies) using ImageJ; brightness and contrast on all images were adjusted using Adobe Photoshop CS5.
EM, tomography, immunogold labeling and ultrastructural morphometry
Specimen preparation, immunoelectron microscopy and electron tomography were performed as previously described in detail.36, 56 Briefly, for morphology, the cells were cultured on sapphire discs suitable for high‐pressure freezing,57 freeze substitution and epoxy resin embedding. Thin sections (80 nm) were used for standard TEM, and 300‐400 nm‐semi‐thick sections for dual‐tilt scanning transmission electron tomography (STEM, with a TECNAI T20G2 from FEI, now: Thermo Scientific, Waltham, MA, USA). For immunogold EM, we used Tokuyasu‐cryosection labeling58 or our recently described method for cryobased pre‐embedding immunogold labeling.56 Primary antibodies were mouse antihumanLAMP1 (EM: 1:10; H4A3; Developmental Studies Hybridoma Bank), rabbit anticathepsin D (EM: 1:100; Ab‐2; Calbiochem), mouse anti‐HA (1:30‐1:100; MMS‐101R; Covance), secondary antibodies were NANOGOLD‐Fab’ goat antimouse and NANOGOLD‐Fab' goat antirabbit IgG (H + L) (1:150; #2002, 2004, respectively, both from Nanoprobes), goat antimouse IgG 5 nm gold (#EM.GAM5, British Biocell) and visualized by silver enhancement (SE) with HQ‐Silver (#2012, Nanoprobes). Processing of digital electron micrographs was optionally carried out with iTEM‐analySIS five software (from EMSIS, Münster, Germany) or Adobe Photoshop V.9, including adjustment of contrast and brightness, gray‐scale modification, sharpening, median and high‐pass filtering. For morphometry, we used samples from >2 independent cell culture experiments (ie, n = 2, with several technical replicates each). Morphometry was carried out on digital micrographs with a MORADA camera (from OSIS) taken at primary magnifications of x11 500 by using measurement tools of the iTEM software.
Phosphoinositide labeling and HPLC‐coupled flow scintillation
HT1808 WT, HT1080 Diaskedin, Myrlysin and Lysperin KO cells were incubated for 24 hours in tritium labeling medium (inositol‐free DMEM [MP Biomedical]) supplemented with 15 μCi/mL myo‐(2‐3H[N]) inositol (Perkin Elmer), 4 mM L‐glutamine (Sigma‐Aldrich), 1x insulin‐transferrin‐selenium‐ethanolamine (Gibco), 10% dialyzed FBS (Gibco) and 1x penicillin‐streptomycin mix (Sigma‐Aldrich). After, labeling medium was removed and replaced with cell culture medium, where cells were incubated in the presence or absence of 200 nM Apilimod (Toronto Research Chemicals) for 1 hour or 10 μM Dorsomorphin for 3 hours. Following, cells were lysed on ice with 4.5% perchloric acid (vol/vol) for 15 minutes then pelleted at 12 000g for 10 minutes at 4°C. Pellets were washed with 1 mL of ice‐cold 100 mM EDTA, pH 8.0, then sonicated in 50 μL of water. Samples were incubated in phospholipid deacylation reagent (10.7% methylamine, 45.7% methanol and 11.4% 1‐butanol [vol/vol]) for 60 minutes at 53°C. Samples were washed in water twice and dried with a speed vacuum. Dried samples were resuspended in a 1.5:1 ratio of water to extraction reagent (1‐butanol/ethyl ether/ethyl formate [20:4:1]), vortexed for 5 minutes, and centrifuged for 2 minutes at max speed. The aqueous layer was isolated and extracted twice more, then vacuum dried and resuspended in 50 μL of water. Samples were then separated by HPLC (Agilent Technologies). For each sample, equal counts of tritium were separated using an anion exchange 4.6 × 250‐mm column (Phenomenex) and subjected to a gradient of 1 M (NH4)2HPO4, pH 3.8 and water. For details of HPLC separation protocol see Ho et al. (2016).60 The radiolabeled eluate was detected by β‐RAM 4 (LabLogic) at a 2:1 ratio of scintillation fluid to eluate and analyzed with Laura 4 software. For quantification, all phosphoinositide species levels were normalized against the parent phosphatidylinositol peak.
Quantification and statistical tests
Endosomal count in HeLa cells was based on 10 cells per phenotype, where endosomes were automatically counted using Imaris software. Endosomal diameter in HeLa cells was based on measurements of at least 100 endosomes from at least six cells per genotype imaged. The percentage of cells, displaying enlarged late endosomes in HT1080 cells was determined, based on acquired immunofluorescent images, using LAMP1 antibody, where at least 300 cells from a minimum of three biological replicates were assigned to either “normal” or “enlarged” group based on general size and abundancy of late endosomes. These were quantified by applying an unpaired Student's t test (*P ≤ .05; **P ≤ .01; ***P ≤ .001).
AUTHOR CONTRIBUTIONS
T.E.Y. as first author designed and performed experiments, and wrote the manuscript. V.E.B.H., M.W.H., G.F.V. and C.H. designed and performed experiments. S.G. designed and provided constructs, G.L. contributed to the statistical analyses. T.S., D.T. and R.J.B. designed experiments, contributed conceptually and in the writing of the manuscript. L.A.H. initiated and supervised the project, designed experiments and wrote the manuscript together with M.W.H. as corresponding authors.Figure S1. An overview of the endosomal system of HT1080 WT cells, labeling of oversized endocytic compartments in HT1080 WT cells with lysosomal markers and a subcellular fractionation of BORC deletion mutants.Figure S2. Effect of Chloroquine and a selection of other chemical inhibitors on the frequency of the characteristic enlarged late endosomes in BORC deletion mutants in HT1080.Figure S3. Schematically where VPS34IN and YM201636 block PI(3,5)P2 production; furthermore, the effect of these inhibitors on endosomal size in HeLa cells, and the effect of Apilimod on PtdInsP production in HT1080 WT and Diaskedin KO cells are shown.Figure S4. The effect of AMPK and ERK inhibition on the formation of characteristic enlarged endosomes in HT1080 cells.Figure S5. A subcellular fractionation of HeLa WT cells, where VPS34IN and YM201636 inhibitors were used and a model for the proposed BORC‐AMPK‐PIKfyve interaction.Click here for additional data file.Movie S1. DQBSA uptake and lysosomal movement in WT and Diaskedin KO HT1080 cells.Click here for additional data file.Movie S2. HeLa WT and Diaskedin KO cells, stably expressing LAMP1 NeonGreen, employing live cell STED imaging.Click here for additional data file.Movie S3. A selected magnification, taken from Movie S2Click here for additional data file.Movie S4. An electron tomographic reconstruction and modeling of tubule forming late endosomal compartments in HT1080 WT cells upon 2h YM201636 inhibition and subsequent washout.Click here for additional data file.Movie S5. An electron tomographic reconstruction and modeling of tubule forming late endosomal compartments in HT1080 Diaskedin KO cells upon 2h YM201636 inhibition and subsequent washout.Click here for additional data file.
Authors: Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: Michael W Hess; Georg F Vogel; Teodor E Yordanov; Barbara Witting; Karin Gutleben; Hannes L Ebner; Mariana E G de Araujo; Przemyslaw A Filipek; Lukas A Huber Journal: Traffic Date: 2018-05-21 Impact factor: 6.215
Authors: Viktor I Korolchuk; Shinji Saiki; Maike Lichtenberg; Farah H Siddiqi; Esteban A Roberts; Sara Imarisio; Luca Jahreiss; Sovan Sarkar; Marie Futter; Fiona M Menzies; Cahir J O'Kane; Vojo Deretic; David C Rubinsztein Journal: Nat Cell Biol Date: 2011-03-13 Impact factor: 28.824
Authors: Teodor E Yordanov; Victoria E B Hipolito; Gudrun Liebscher; Georg F Vogel; Taras Stasyk; Caroline Herrmann; Stephan Geley; David Teis; Roberto J Botelho; Michael W Hess; Lukas A Huber Journal: Traffic Date: 2019-09 Impact factor: 6.215
Authors: Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier Journal: Autophagy Date: 2016 Impact factor: 16.016
Authors: Diego L Medina; Simone Di Paola; Ivana Peluso; Andrea Armani; Diego De Stefani; Rossella Venditti; Sandro Montefusco; Anna Scotto-Rosato; Carolina Prezioso; Alison Forrester; Carmine Settembre; Wuyang Wang; Qiong Gao; Haoxing Xu; Marco Sandri; Rosario Rizzuto; Maria Antonietta De Matteis; Andrea Ballabio Journal: Nat Cell Biol Date: 2015-03 Impact factor: 28.824
Authors: Sai Srinivas Panapakkam Giridharan; Guangming Luo; Pilar Rivero-Rios; Noah Steinfeld; Helene Tronchere; Amika Singla; Ezra Burstein; Daniel D Billadeau; Michael A Sutton; Lois S Weisman Journal: Elife Date: 2022-01-18 Impact factor: 8.140
Authors: Teodor E Yordanov; Victoria E B Hipolito; Gudrun Liebscher; Georg F Vogel; Taras Stasyk; Caroline Herrmann; Stephan Geley; David Teis; Roberto J Botelho; Michael W Hess; Lukas A Huber Journal: Traffic Date: 2019-09 Impact factor: 6.215
Authors: Pedro H P R Carvalho; Jose R Correa; Karen L R Paiva; Daniel F S Machado; Jackson D Scholten; Brenno A D Neto Journal: Beilstein J Org Chem Date: 2019-11-06 Impact factor: 2.883
Authors: Michelle E Maxson; Yazan M Abbas; Jing Ze Wu; Jonathan D Plumb; Sergio Grinstein; John L Rubinstein Journal: J Cell Biol Date: 2022-01-13 Impact factor: 8.077